These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

649 related articles for article (PubMed ID: 22576213)

  • 1. Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents.
    Birkbak NJ; Wang ZC; Kim JY; Eklund AC; Li Q; Tian R; Bowman-Colin C; Li Y; Greene-Colozzi A; Iglehart JD; Tung N; Ryan PD; Garber JE; Silver DP; Szallasi Z; Richardson AL
    Cancer Discov; 2012 Apr; 2(4):366-375. PubMed ID: 22576213
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer.
    Telli ML; Timms KM; Reid J; Hennessy B; Mills GB; Jensen KC; Szallasi Z; Barry WT; Winer EP; Tung NM; Isakoff SJ; Ryan PD; Greene-Colozzi A; Gutin A; Sangale Z; Iliev D; Neff C; Abkevich V; Jones JT; Lanchbury JS; Hartman AR; Garber JE; Ford JM; Silver DP; Richardson AL
    Clin Cancer Res; 2016 Aug; 22(15):3764-73. PubMed ID: 26957554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes.
    Timms KM; Abkevich V; Hughes E; Neff C; Reid J; Morris B; Kalva S; Potter J; Tran TV; Chen J; Iliev D; Sangale Z; Tikishvili E; Perry M; Zharkikh A; Gutin A; Lanchbury JS
    Breast Cancer Res; 2014 Dec; 16(6):475. PubMed ID: 25475740
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential contributory roles of nucleotide excision and homologous recombination repair for enhancing cisplatin sensitivity in human ovarian cancer cells.
    Wang QE; Milum K; Han C; Huang YW; Wani G; Thomale J; Wani AA
    Mol Cancer; 2011 Mar; 10():24. PubMed ID: 21385444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor mutation burden forecasts outcome in ovarian cancer with BRCA1 or BRCA2 mutations.
    Birkbak NJ; Kochupurakkal B; Izarzugaza JM; Eklund AC; Li Y; Liu J; Szallasi Z; Matulonis UA; Richardson AL; Iglehart JD; Wang ZC
    PLoS One; 2013; 8(11):e80023. PubMed ID: 24265793
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genomic Characterization of Cisplatin Response Uncovers Priming of Cisplatin-Induced Genes in a Resistant Cell Line.
    Golan Berman H; Chauhan P; Shalev S; Hassanain H; Parnas A; Adar S
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34071702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Replication Protein A Availability during DNA Replication Stress Is a Major Determinant of Cisplatin Resistance in Ovarian Cancer Cells.
    Bélanger F; Fortier E; Dubé M; Lemay JF; Buisson R; Masson JY; Elsherbiny A; Costantino S; Carmona E; Mes-Masson AM; Wurtele H; Drobetsky E
    Cancer Res; 2018 Oct; 78(19):5561-5573. PubMed ID: 30072396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting DNA repair and replication stress in the treatment of ovarian cancer.
    Murai J
    Int J Clin Oncol; 2017 Aug; 22(4):619-628. PubMed ID: 28643177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Downregulation of RIF1 Enhances Sensitivity to Platinum-Based Chemotherapy in Epithelial Ovarian Cancer (EOC) by Regulating Nucleotide Excision Repair (NER) Pathway.
    Liu YB; Mei Y; Tian ZW; Long J; Luo CH; Zhou HH
    Cell Physiol Biochem; 2018; 46(5):1971-1984. PubMed ID: 29719287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRCA1 epigenetic inactivation predicts sensitivity to platinum-based chemotherapy in breast and ovarian cancer.
    Stefansson OA; Villanueva A; Vidal A; Martí L; Esteller M
    Epigenetics; 2012 Nov; 7(11):1225-9. PubMed ID: 23069641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RAD6B is a major mediator of triple negative breast cancer cisplatin resistance: Regulation of translesion synthesis/Fanconi anemia crosstalk and BRCA1 independence.
    Haynes B; Gajan A; Nangia-Makker P; Shekhar MP
    Biochim Biophys Acta Mol Basis Dis; 2020 Jan; 1866(1):165561. PubMed ID: 31639439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A meta-analysis of reversion mutations in BRCA genes identifies signatures of DNA end-joining repair mechanisms driving therapy resistance.
    Tobalina L; Armenia J; Irving E; O'Connor MJ; Forment JV
    Ann Oncol; 2021 Jan; 32(1):103-112. PubMed ID: 33091561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer.
    Yang D; Khan S; Sun Y; Hess K; Shmulevich I; Sood AK; Zhang W
    JAMA; 2011 Oct; 306(14):1557-65. PubMed ID: 21990299
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Absence of evidence for allelic loss or allelic gain for ERCC1 or for XPD in human ovarian cancer cells and tissues.
    Yu JJ; Bicher A; Ma YK; Bostick-Bruton F; Reed E
    Cancer Lett; 2000 Apr; 151(2):127-32. PubMed ID: 10738106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ACTL6A promotes repair of cisplatin-induced DNA damage, a new mechanism of platinum resistance in cancer.
    Xiao Y; Lin FT; Lin WC
    Proc Natl Acad Sci U S A; 2021 Jan; 118(3):. PubMed ID: 33408251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genomic Complexity Profiling Reveals That HORMAD1 Overexpression Contributes to Homologous Recombination Deficiency in Triple-Negative Breast Cancers.
    Watkins J; Weekes D; Shah V; Gazinska P; Joshi S; Sidhu B; Gillett C; Pinder S; Vanoli F; Jasin M; Mayrhofer M; Isaksson A; Cheang MC; Mirza H; Frankum J; Lord CJ; Ashworth A; Vinayak S; Ford JM; Telli ML; Grigoriadis A; Tutt AN
    Cancer Discov; 2015 May; 5(5):488-505. PubMed ID: 25770156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Checkpoint kinase 2 (Chk2) supports sensitivity to platinum-based treatment in high grade serous ovarian cancer.
    Alkema NG; Tomar T; van der Zee AG; Everts M; Meersma GJ; Hollema H; de Jong S; van Vugt MA; Wisman GB
    Gynecol Oncol; 2014 Jun; 133(3):591-8. PubMed ID: 24657486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced sensitivity to cisplatin and gemcitabine in Brca1-deficient murine mammary epithelial cells.
    Alli E; Sharma VB; Hartman AR; Lin PS; McPherson L; Ford JM
    BMC Pharmacol; 2011 Jul; 11():7. PubMed ID: 21771338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Abnormalities of DNA repair and gynecological cancers].
    Auguste A; Leary A
    Bull Cancer; 2017 Nov; 104(11):971-980. PubMed ID: 29054544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval.
    Fong PC; Yap TA; Boss DS; Carden CP; Mergui-Roelvink M; Gourley C; De Greve J; Lubinski J; Shanley S; Messiou C; A'Hern R; Tutt A; Ashworth A; Stone J; Carmichael J; Schellens JH; de Bono JS; Kaye SB
    J Clin Oncol; 2010 May; 28(15):2512-9. PubMed ID: 20406929
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.